Bryan Hassell is the CEO and Founder at Nirrin Technologies. Prior to Nirrin, Bryan served as a Principal Investigator for the U.S. Department of Defense (DOD), evaluating the innovation potential of small businesses to help address national security challenges and ensure technological superiority for the U.S. Navy and U.S. Special Ops Command. He held a role as an Investment Associate with Anzu Partners, a venture capital/PE firm concentrating on industrial breakthrough technologies, leading diligence on investments into their industrial and life science portfolio companies. Bryan received a Ph.D. in Applied Physics from Harvard University where he developed an organ-on-a-chip microfluidic model of EGFR non-small cell lung cancer to explore tyrosine kinase inhibitor resistance and signaling dynamics in vitro. This work led a $80M DARPA grant and launch of Emulate Bio (valued over $1B and on the Deloitte Technology Fast 500™ list).